文献速递乳房整形与再造美容整形

保留乳头乳房切除术前分期乳房固定术:提高乳房再造的安全性与外观

Staged Mastopexy before Nipple-Sparing Mastectomy: Improving Safety and Appearance in Breast Reconstruction.
PubMed 文献 · Plast Reconstr Surg · 2023-06-19

回顾性分析47例有乳腺癌遗传易感性的患者(84侧乳房),在保留乳头乳房切除术前先行分期乳房缩小/固定术,第二期采用游离腹部皮瓣或假体联合脱细胞真皮基质再造。两期间隔11.5个月(范围1.3至23.6个月),术后仅1侧(1.2%)出现乳头乳晕复合体表皮松解、2侧(2.4%)出现部分皮瓣坏死,作者认为该分期方案安全、缺血并发症风险低。

要点

  • 47例(84侧)遗传易感性患者行分期乳房缩小/固定后再行保留乳头乳房切除与再造。
  • 再造方式:游离腹部皮瓣12侧(14.3%)、组织扩张器6侧(7.1%)、永久性胸肌下假体联合脱细胞真皮基质66侧(78.6%)。
  • 缺血并发症:乳头乳晕复合体表皮松解1侧(1.2%),部分乳房切除皮瓣坏死2侧(2.4%)。

核心结论

  • 在保留乳头乳房切除与再造前先行乳房固定或乳房缩小是安全的手术,缺血并发症风险低。

研究设计与样本

  • 回顾性分析,纳入作者所在机构中有乳腺癌遗传易感性、在保留乳头乳房切除与再造前接受分期乳房缩小/乳房固定的患者。
  • 原位病变或浸润性癌患者的第一期手术为肿块切除联合肿瘤整形乳房缩小/固定。
  • 第二期乳房再造采用游离腹部皮瓣或乳房假体联合脱细胞真皮基质。

主要发现

  • 共47例患者(84侧乳房)接受该分期方案,全部患者均有乳腺癌遗传易感性。
  • 两期手术间隔为11.5个月(范围1.3至23.6个月)。
  • 12侧乳房(14.3%)采用游离腹部皮瓣再造,6侧(7.1%)采用组织扩张器,66侧(78.6%)采用永久性胸肌下假体联合脱细胞真皮基质。
  • 术后出现1例乳头乳晕复合体表皮松解(1.2%),2例部分乳房切除皮瓣坏死(2.4%)。
  • 完成再造后的平均随访时间为8.3个月。

关键数值与推荐

  • 证据等级:治疗性,IV级。

临床怎么用

  • 作者认为,在保留乳头乳房切除与再造前先行乳房固定或乳房缩小是安全的手术,缺血并发症风险低。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Breast reconstruction following nipple-sparing mastectomy (NSM) in patients with large or ptotic breasts remains challenging because of the risk of ischemic complications and the difficulty in managing the redundant skin envelope. Staged mastopexy or breast reduction before the mastectomy/reconstruction has been shown to decrease the risk of complications and improve clinical outcomes. METHODS: A retrospective analysis was conducted of patients with a genetic predisposition to breast cancer who underwent staged breast reduction/mastopexy before NSM and reconstruction in the authors' institution. In patients with in situ disease or invasive cancer, the first stage consisted of lumpectomy and oncoplastic reduction/mastopexy. Breast reconstruction at the second stage was performed with free abdominal flaps or breast implants and acellular dermal matrix. Data regarding the ischemic complications were recorded. RESULTS: In total, 47 patients (84 breasts) underwent this staged approach. All patients had a genetic predisposition to breast cancer. The time interval between the two stages was 11.5 months (range, 1.3 to 23.6 months). Twelve breasts (14.3%) were reconstructed with free abdominal flaps, six (7.1%) with tissue expanders, and 66 (78.6%) with permanent subpectoral implants and acellular dermal matrix. There was one case of postoperative superficial nipple-areola complex epidermolysis (1.2%), and two cases of partial mastectomy skin flap necrosis (2.4%). The mean follow-up time after completion of reconstruction was 8.3 months. CONCLUSION: Mastopexy or breast reduction before NSM and reconstruction is a safe procedure with a low risk of ischemic complications. CLINICAL QUESTION/LEVEL OF EVIDENCE: Therapeutic, IV.

来源:Plast Reconstr Surg,查看原文。版权归原作者所有。

引用

  1. Awaida CJ, Bernier C, Bou-Merhi JS, et al. Staged Mastopexy before Nipple-Sparing Mastectomy: Improving Safety and Appearance in Breast Reconstruction. Plast Reconstr Surg. 2023. PMID: 37335584. doi:10.1097/PRS.0000000000010823

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。